Dan Yang

Dr. Dan Yang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
KJKaili Jin
Kaili Jin
XLXianlei Lin
Xianlei Lin
XXXiaoting Xia
Xiaoting Xia
HYHuiling Ye
Huiling Ye
DYDan Yang
Dan Yang
RWRongyun Wang
Rongyun Wang
Background: Platinum-based chemotherapy significantly increases the risk of nausea and vomiting, which can impair the treatment’s efficacy and the patient’s quality of life. This meta-analysis examines the incidence and risk factors of platinum-based chemotherapy-induced nausea and vomiting (PINV) in patients treated with this chemotherapy. Methods: This systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. We conducted a literature search in the databases PubMed, Embase, Web of Science, WanFang, China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure (CNKI), and Chinese Medical Association Journal Database (CMAJD) through to 20 January 2025. Studies that reported the incidence and identified risk factors of nausea and vomiting specifically in patients receiving platinum-based chemotherapy were included in the review. The data were extracted independently by two reviewers. The odds ratios (ORs) for each risk factor were calculated from the included studies. Sensitivity analyses and additional subgroup analyses were performed to ensure the robustness of our findings. Results: This meta-analysis included 32 studies involving 14,207 participants. Female sex (OR = 2.363, 95% CI = 1.363–4.096, p = 0.002), anxiety (OR = 1.689, 95% CI = 1.057–2.700, p = 0.028), fatigue (OR = 1.413, 95% CI = 1.145–1.744, p = 0.001), motion sickness (OR = 1.816, 95% CI = 1.266–2.605, p = 0.001), and a history of vomiting during chemotherapy (OR = 2.728, 95% CI = 1.468–5.069, p = 0.002) were significantly associated with an increased risk of PINV. Conclusion: Female sex, anxiety, fatigue, motion sickness, and a history of vomiting during chemotherapy increase the risk of PINV during platinum-based treatments.